Skip to content
Inciteful Med

The Road to Remission: Standard of Care Treatment

Last updated:

The primary goal of Behçet's disease treatment is achieving remission and preventing organ damage. Treatment is highly personalized based on EULAR guidelines, using medications like colchicine for ulcers, biologics for eye inflammation, and powerful immunosuppressants for vascular involvement.

Key Takeaways

  • • Treatment for Behçet's disease is highly tailored to the specific organs affected, guided by EULAR protocols.
  • • Colchicine is typically the first-line defense for managing painful mucocutaneous symptoms like mouth and genital ulcers.
  • • Aggressive intervention with biologics or immunosuppressants is critical for eye, vascular, or neurological involvement to prevent long-term damage.
  • • Unlike typical blood clots, clots caused by Behçet's disease are driven by vascular inflammation and primarily treated with immunosuppressants rather than blood thinners.
  • • Achieving remission and preventing permanent organ damage are the primary goals of all Behçet's disease therapies.

Treatment for Behçet’s disease has advanced significantly in recent years. Because it is a multisystem disorder, there is no “one-size-fits-all” pill. Instead, doctors follow the EULAR (European Alliance of Associations for Rheumatology) guidelines, which tailor treatment based on which specific organs are affected [1][2].

The primary goal of any treatment is to achieve remission (a state where there is no active inflammation) and prevent permanent damage to vital organs like the eyes, brain, and blood vessels [3][4].

Managing Mucocutaneous Symptoms (Skin & Mouth)

For many patients, the journey starts with managing painful ulcers and skin lesions.

  • Colchicine: This is often the first-line “gold standard” for preventing mouth and genital ulcers, as well as joint pain [1][5].
  • Topical Treatments: For mild flares, doctors may prescribe steroid-based creams or gels to apply directly to the ulcers.
  • Apremilast: If ulcers are frequent and don’t respond to colchicine, apremilast is a newer systemic pill specifically recommended for severe oral sores [1][6].

Protecting the Eyes (Ocular Involvement)

When inflammation affects the eyes, treatment must be aggressive to prevent vision loss [1].

  • TNF-alpha Inhibitors: Medications like adalimumab or infliximab (biologics) have revolutionized care. They are often used for “posterior” uveitis (inflammation in the back of the eye) because they act quickly and can often allow patients to stop taking high-dose steroids [7][8][9].
  • Immunosuppressants: Conventional drugs like azathioprine are also commonly used to maintain eye health over the long term [1].

Severe Involvement: Vascular & Neurological

Involvements of the blood vessels (Vascular Behçet’s) or the nervous system (Neuro-Behçet’s) are considered medical priorities that require intensive therapy [10][11].

  • Induction Therapy: To stop a severe flare quickly, doctors often use “pulse” therapy—high doses of intravenous corticosteroids followed by a potent immunosuppressant like cyclophosphamide [12][13].
  • Biologics: Infliximab is increasingly used as an alternative for severe neurological or vascular flares, as it may work more quickly and with fewer side effects than cyclophosphamide [13][14].

The Great Debate: Blood Thinners vs. Immunosuppressants

In standard medicine, a blood clot is usually treated with anticoagulants (blood thinners). However, in Behçet’s, the rules are different:

  • Inflammation-Driven Clots: Clots in Behçet’s are caused by an inflamed blood vessel wall, not “thick blood.” Therefore, the most important treatment is an immunosuppressant to stop the inflammation at its source [15][16].
  • The Risk of Thinners: Anticoagulants can be dangerous if a patient has an undiagnosed aneurysm (a weakened, bulging artery), as they could increase the risk of a life-threatening bleed [15][17]. While some doctors use a combination of both in very specific scenarios, suppressing the immune system remains the absolute priority [18][19].

Staging Your Care: A Decision Tree

Involvement First-Line Treatment Escalation (If First-Line Fails)
Mouth/Skin/Joints Colchicine + Topicals [1] Apremilast or Azathioprine [1]
Eyes (Uveitis) Azathioprine or Steroids [1] TNF-Inhibitors (Adalimumab) [9]
Vascular/Neuro High-Dose Steroids + Immunosuppressant (e.g., Cyclophosphamide) or Biologic [12] Switch to alternative Biologic (e.g., Infliximab or Tocilizumab) [14]
Gastrointestinal 5-ASA or Steroids [1] TNF-Inhibitors (Infliximab) [20]

Your care team will monitor your progress using blood markers like CRP and ESR to ensure the inflammation is truly under control [21][22]. For more on how this team is structured, see Building Your Care Team.

Frequently Asked Questions

What is the first-line treatment for Behçet's disease mouth and genital ulcers?
Colchicine is considered the gold standard first-line treatment for managing mouth ulcers, genital ulcers, and joint pain. If your ulcers do not respond to colchicine or topical creams, your doctor may recommend a newer systemic medication called apremilast.
How is eye inflammation treated in Behçet's disease?
Severe eye inflammation, such as posterior uveitis, requires aggressive treatment to prevent permanent vision loss. Doctors often prescribe fast-acting TNF-alpha inhibitors like adalimumab or infliximab to rapidly control inflammation and protect the eyes.
Why are immunosuppressants preferred over blood thinners for clots in Behçet's?
Blood clots in Behçet's disease are caused by severe inflammation of the blood vessel walls, rather than typical clotting issues. Strong immunosuppressants are used to target this inflammation directly. Traditional blood thinners can actually be dangerous due to the risk of bleeding from an undiagnosed aneurysm.
How do doctors treat severe neurological or vascular Behçet's disease?
When the condition affects the nervous system or major blood vessels, doctors typically use aggressive pulse therapy. This involves high doses of intravenous corticosteroids followed by potent immunosuppressants like cyclophosphamide or biologic drugs to quickly stop severe flares.
How will I know if my Behçet's disease treatment is working?
Your care team will monitor your progress using specific blood markers like CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate). These tests help confirm that the underlying inflammation is truly under control and that the medication is working.

Questions for Your Doctor

  • • Which 'phenotype' or subtype of Behçet’s am I being treated for, and does my plan follow the 2018 EULAR guidelines?
  • • Since I have recurrent ulcers, is colchicine the first step, or should we consider apremilast if they don't respond quickly?
  • • For my eye or vascular symptoms, should we start a biologic like adalimumab now to prevent long-term damage?
  • • If I have a blood clot, why is an immunosuppressant more important than a blood thinner in my specific case?
  • • What is our 'treatment target'—how will we know if the medication is working, and when will we decide to switch?

Questions for You

  • • How many days or weeks of relief am I getting between flares on my current treatment?
  • • Am I able to perform my daily activities without significant pain or fatigue?
  • • Have I noticed any new or worsening symptoms since starting my current medication?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [An update on Behçet's syndrome].

    Xenitidis T, Henes JC

    Deutsche medizinische Wochenschrift (1946) 2023; (148(17)):1129-1134 doi:10.1055/a-1958-2338.

    PMID: 37611579
  2. 2

    2018 update of the EULAR recommendations for the management of Behçet's syndrome.

    Hatemi G, Christensen R, Bang D, et al.

    Annals of the rheumatic diseases 2018; (77(6)):808-818 doi:10.1136/annrheumdis-2018-213225.

    PMID: 29625968
  3. 3

    Treating the Different Phenotypes of Behçet's Syndrome.

    Bettiol A, Hatemi G, Vannozzi L, et al.

    Frontiers in immunology 2019; (10()):2830 doi:10.3389/fimmu.2019.02830.

    PMID: 31921115
  4. 4

    Behçet's Syndrome Apart From the Triple Symptom Complex: Vascular, Neurologic, Gastrointestinal, and Musculoskeletal Manifestations. A Mini Review.

    Kötter I, Lötscher F

    Frontiers in medicine 2021; (8()):639758 doi:10.3389/fmed.2021.639758.

    PMID: 33898481
  5. 5

    [An update on Behçet's syndrome].

    Xenitidis T, Henes JC

    Laryngo- rhino- otologie 2024; (103(5)):352-357 doi:10.1055/a-2249-2116.

    PMID: 38330997
  6. 6

    The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease.

    Wang Z, Zu X, Xiong S, et al.

    Clinical therapeutics 2023; (45(2)):162-176 doi:10.1016/j.clinthera.2023.01.004.

    PMID: 36732153
  7. 7

    Early administration of adalimumab for paediatric uveitis due to Behçet's disease.

    Hiyama T, Harada Y, Doi T, Kiuchi Y

    Pediatric rheumatology online journal 2019; (17(1)):29 doi:10.1186/s12969-019-0333-6.

    PMID: 31182107
  8. 8

    Long-Term Outcomes of Uveoretinitis in Behçet's Disease in the Era of Biologic Treatments: A 10-Year Follow-Up Study.

    Sugawara R, Usui Y, Tsubota K, Goto H

    Ocular immunology and inflammation 2025; (33(6)):913-919 doi:10.1080/09273948.2025.2467435.

    PMID: 39980310
  9. 9

    Management of Behçet's syndrome.

    Ozguler Y, Hatemi G

    Current opinion in rheumatology 2016; (28(1)):45-50 doi:10.1097/BOR.0000000000000231.

    PMID: 26555450
  10. 10

    Pulmonary Artery Aneurysm in Behcet Disease: Medical, Endovascular or Surgical Intervention.

    Samreen I, Darji P, Genobaga S, et al.

    Cureus 2023; (15(11)):e49368 doi:10.7759/cureus.49368.

    PMID: 38146562
  11. 11

    Focus on neuro-Behçet's disease: A review.

    Caruso P, Moretti R

    Neurology India 2018; (66(6)):1619-1628 doi:10.4103/0028-3886.246252.

    PMID: 30504554
  12. 12

    Behçet's Disease and Nervous System Involvement.

    Kürtüncü M, Tüzün E, Akman-Demir G

    Current treatment options in neurology 2016; (18(5)):19 doi:10.1007/s11940-016-0405-6.

    PMID: 27007988
  13. 13

    Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.

    Saadoun D, Maalouf G, Vieira M, et al.

    NEJM evidence 2024; (3(11)):EVIDoa2300354 doi:10.1056/EVIDoa2300354.

    PMID: 39437137
  14. 14

    Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab.

    Karabulut Y

    European journal of rheumatology 2021; (8(4)):223-227 doi:10.5152/eurjrheum.2021.20160.

    PMID: 34554909
  15. 15

    Concurrent Pulmonary Artery Aneurysm, Pulmonary Thrombosis, and Intracardiac Thrombus in Behçet's Disease: A Case Report.

    Alagha OA, Abu ElQomboz AY, Alsarafandi SF

    Cureus 2023; (15(8)):e43993 doi:10.7759/cureus.43993.

    PMID: 37746357
  16. 16

    Arterial and venous involvement in Behçet's syndrome: a narrative review.

    Toledo-Samaniego N, Oblitas CM, Peñaloza-Martínez E, et al.

    Journal of thrombosis and thrombolysis 2022; (54(1)):162-171 doi:10.1007/s11239-022-02637-1.

    PMID: 35182310
  17. 17

    [Hughes-Stovin syndrome: a life-threatening manifestation of Behçet's syndrome].

    Ruffer N, Krusche M, Holl-Ulrich K, et al.

    Zeitschrift fur Rheumatologie 2024; (83(4)):327-333 doi:10.1007/s00393-023-01371-0.

    PMID: 37280333
  18. 18

    Anticoagulants and immunosuppressive therapy for thrombosis in Behçet's syndrome: a systematic review and meta-analysis.

    Chuklin A, Chiasakul T, Uaprasert N

    Journal of thrombosis and haemostasis : JTH 2025; (23(11)):3578-3589 doi:10.1016/j.jtha.2025.07.025.

    PMID: 40769432
  19. 19

    Does anticoagulation in combination with immunosuppressive therapy prevent recurrent thrombosis in Behçet's disease?

    Erol S, Gürün Kaya A, Arslan F, et al.

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2024; (72(4)):387-391 doi:10.1177/10815589241232368.

    PMID: 38357865
  20. 20

    Management of Behçet's disease.

    Alibaz-Oner F, Sawalha AH, Direskeneli H

    Current opinion in rheumatology 2018; (30(3)):238-242 doi:10.1097/BOR.0000000000000497.

    PMID: 29432223
  21. 21

    Predictors of anti-TNF treatment failure in intestinal Behçet's disease: a multicenter retrospective cohort study.

    Xu W, Wu X, Yu Q, et al.

    Clinical rheumatology 2025; (44(9)):3655-3665 doi:10.1007/s10067-025-07581-y.

    PMID: 40668289
  22. 22

    Pan-immune-inflammation value could be a new marker to differentiate between vascular Behçet's disease and non-vascular Behçet's disease.

    Ocak T, Lermı N, Yılmaz Bozkurt Z, et al.

    European review for medical and pharmacological sciences 2024; (28(5)):1751-1759 doi:10.26355/eurrev_202403_35588.

    PMID: 38497857

This page explains standard treatments for Behçet's disease for educational purposes only. Always consult your rheumatologist or multidisciplinary care team before starting or changing any medications.

Stay up to date

Get notified when new research about Behçet disease is published.

No spam. Unsubscribe anytime.